{"name":"Zevra Therapeutics","slug":"zevra","ticker":"ZVRA","exchange":"NASDAQ","domain":"zevra.com","description":"Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture a","hq":"Celebration, FL","founded":2017,"employees":"61","ceo":"Adrian Adams","sector":"Rare Disease / Neurology","stockPrice":9.69,"stockChange":0.01,"stockChangePercent":0.1,"marketCap":"$569M","metrics":{"revenue":106470000,"revenueGrowth":183.4,"grossMargin":84.5,"rdSpend":10161000,"netIncome":83229000,"cash":62406000,"dividendYield":0,"peRatio":7.2,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ZV9 patent cliff ($100M at risk)","drug":"ZV9","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"ZVRA Receives FDA Fast Track Designation for ZV9","summary":"Zevra Therapeutics announced that the FDA has granted Fast Track designation to ZV9, its lead product candidate for the treatment of a rare neurological disorder.","drugName":"ZV9","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"ZVRA Reports Third Quarter 2023 Financial Results","summary":"Zevra Therapeutics reported its third quarter 2023 financial results, with revenue of $10.2 million and a net loss of $23.1 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-21","type":"pipeline","source":"simplywall.st","summary":"Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone - simplywall.st","headline":"Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxQRTlkdC1URUIzRDkybkJiM1AyM0xneDVHWmloQ2JDNUh1LXc4NU9iM09IUTBFN1I0WGlfVWdKYVozM3FFX2VlWlN0Y1dVN0FGdGo3c0NRS1p2d3NJN1ZqT1hvUXppMmJZeHpJdWFJUXdFRUcwelhnZzhyZ0xzcTBzcVpIZHZSTXVQQUw3a1k0Z2UwckVfcWszOThyYXBPQ3VHczltWEZGMldFMmxqSVFyUUV5NjdOZmFFdjllSzMwYTlNN1ROdG40b1NTS1c3aTVDT3g0ckk0QnliVnJQUF95dlFORHp6cmd4U3RHN3NKTFhvUUU5dWtnWF91THNGMkd4V1ZPQ1RTc2MtUDFLQzNQVGF6ajJmWnhWSTA2b1hOSjVBZkNyb3VsN0ZIY2VZc3Bu?oc=5","date":"2026-03-12","type":"pipeline","source":"The Globe and Mail","summary":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail","headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTlB0YzFxd2J2WWJuR01VZGU2NHhUMU9FRFY2TUdHLXFDLThXMVJUM2tBLXZOLTNZZTZxZ0NsT0hfNkpCVnRWSXYtZS1qSjBNaE9va3lZQmI1Tk5ZdE40YW9mVHgzdVFNMWJtSndDc294RnNtc3FqOTN1eXY4clRRRnFOTmJqUS1ySXZHQVgxb0t1MWhMdU1BRGdxc25EM0FDTzJaUTlYRmV2ZGdhTE50Qllxel8xRU5Vb2s5eWUwQm9rT3N6ZjU3Y2h6YldvM05TenpwWlpQMTZMX3JJc1BjdlVWS3NxZ1nSAewBQVVfeXFMUEpsSkRHNm9kRGNnaDFEaWh3RExzNW1GUjFwQllkLU55bGREeVhybGVJZ1dmTGFleHdJQVNWSllYdEdTdlZQSHZ5UFYzaUFkWFpVeXBycFEyNlhJM0J6OGtkUlFwSGpzWExia2FWYWdVTWIyaVR3MUU3YlZzbkFycHMydGN6TmxQYnRBeDM1Z2djb3R2dlBtUkVkYW5uTlA5dDRwRkRFbG94Y1NFcHp5dTRCQ1lxWExzREdSYU9SS1V2MTBPYW5SbC0teHBuWkRldmpXMG0zRk5PNjh5c2VvcVNlX1ZSdU1VUG5FdkU?oc=5","date":"2026-03-11","type":"earnings","source":"simplywall.st","summary":"Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case - simplywall.st","headline":"Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNZU9EMkEtRF9LcnVIbHJSYXRRNW9LWGp6SDM0blhFVEZGN0J5bzl0dkw2SmszTjRCc0txSVhIVXlibzM5c3dPWElrbGJEaW1JbXZHZEhvT2ZNclNaY2R6MWJGSVI5SGIydDhnRzNrS2Joall0WGszXzd1U2pqNEVYVm00X0o4SjJ3eUd0cDQ5NDNRdw?oc=5","date":"2026-03-11","type":"pipeline","source":"Yahoo Finance","summary":"Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance","headline":"Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-10","type":"earnings","source":"simplywall.st","summary":"Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA) - simplywall.st","headline":"Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA)","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPSnQ3MmczQmt4czRyT3pBYnZLWjcwN3ZEXzhGYUs0UExnODB3VFo3bk5TaExzd3ZjVjRoOXpkLUV6cGxKRHIxSktQaGlkblNzekJicmgzekxCUTg0a041YjBpTDRSNEoxT3dpSFluMmNTSm9rQ2k1b0FuNjNfcl9CdVpEN3RuYlVFNHlYUXZXSjB0dklEYWZISjNMMGotWF9XT0d3UFZaUW1YRG84bDRNc3lzRQ?oc=5","date":"2026-03-05","type":"pipeline","source":"Stock Titan","summary":"25-year biopharma finance leader Justin Renz joins Zevra as CFO - Stock Titan","headline":"25-year biopharma finance leader Justin Renz joins Zevra as CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPUGk3MUZLWWdyZnVMSG9oaGh4MTNOelRXakxvNzFaY2M5OEt2Q0t2NUU3RUxKQ3pjOGR1NVRIQ1Fxa3FHVmlBRmlpdk5pM0tGUDJRM01CWFRXMjJDaDN4MHVRZ19vOTVCWTRNb2owdnA3TGdNM1JLaWRxams4Y0NRbDU0cTBrZjM2aDVILVkwWUgyMjZXUTZJOEcxTzkxUFZxWDExblRzU3N6T1h6SXJFQTVHbnNGeEYteVJTZGFTcFRxQ0FzTVdaU2dsNUdudnIzak9TWGczQXFnNDY4RVRDNzdZUDBHenVxWHlVazR3NW9pNkJBY0lJVi1CY1gzSjFJcTVqZjFoMG1zTzRFbWRTd2lKMGJ1WlU?oc=5","date":"2025-12-30","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNVjA5ZWJjdGp2SlllLWpPWXlOQk5DNU9ZVW9Kd0htYlpxS1VWQV9sazI0eTFiZGZ3d3BRME9TMmRnMnJEcDVZd3g4UmZYVTl1OFdpdlZIZmxNLW0tV3ZLMEp0N2pidi1GWmViNENHVlkyb2lsWFdGMXlpaHZYd05Hb0RhQnZCRmlORjk2YUNRU01BbEJNc0xnSm1MWHJDN0VDZFNIS1IyVmxXd3VnZVRxUXFjVWt5Q3RoT0xqcDJONmktNmlZenhCdGNKRl9UR1pJdTdELUl0QXozUQ?oc=5","date":"2025-12-02","type":"pipeline","source":"Quiver Quantitative","summary":"Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors, Announces Retirement of Wendy Dixon - Quiver Quantitative","headline":"Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors, Announces Retirement of Wendy Dixon","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-08","type":"pipeline","source":"simplywall.st","summary":"Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st","headline":"Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPczFRckZTVUhST0JKVTRyR2FqQ09fSWZYMFItTF9xM1RpODRLT0tTNUswbWxoVkV0d1NSRkJDaWMxb2wxY1ZFeVhqRWZ4OEh5aHVncWpxTEhMa0xxazB4ek05MmZiZTdOcGJGdkQ5X0JheWY1M1pqYkRVTFZDam9lRzV2aEM?oc=5","date":"2025-09-25","type":"pipeline","source":"Yahoo Finance","summary":"Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? - Yahoo Finance","headline":"Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFBCd2dFXzA5cTZiUGcyYlMxcGR0elZacjB6R3hsZEJHTW1qb3U2SmhBb1hqZlg3WW4wZnlIa0xTNHNtSlRNem1zdmVHd2VyTnZ3MUk4MHg2Z1k1MW5HNVRaUTVscw?oc=5","date":"2025-09-24","type":"pipeline","source":"TradingView","summary":"ETFs Investing in Zevra Therapeutics, Inc. Stocks - TradingView","headline":"ETFs Investing in Zevra Therapeutics, Inc. Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5DaHg2X1pNN3VIaGc3bzNTTjRMZHYwcmh0dmk4SzdDY1pDeXB1dmRoVkg0Qmg4Vk45azB5R0VTRjk5WVJKTEg1ZExuVkxXdlZLdWxr?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ZVRA Stock Price, News & Analysis - Stock Titan","headline":"ZVRA Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"ZV9","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BioMarin Pharmaceutical Inc.","Pfizer Inc.","Alexion Pharmaceuticals Inc."],"therapeuticFocus":["Rare Diseases","Neurology"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":0,"period":"2015-12-31"},{"value":0,"period":"2015-09-30"},{"value":0,"period":"2015-06-30"},{"value":0,"period":"2015-03-31"},{"value":0,"period":"2014-12-31"},{"value":0,"period":"2014-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":10161000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":83229000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":62406000,"cashHistory":[],"totalAssets":284731000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":9.69,"previousClose":9.68,"fiftyTwoWeekHigh":13.16,"fiftyTwoWeekLow":6.19,"fiftyTwoWeekRange":"6.19 - 13.16","fiftyDayAverage":9.13,"twoHundredDayAverage":9.49,"beta":0.89,"enterpriseValue":440523136,"forwardPE":6.4,"priceToBook":3.56,"priceToSales":5.34,"enterpriseToRevenue":4.14,"enterpriseToEbitda":-2461.02,"pegRatio":0,"ebitda":-179000,"ebitdaMargin":-0.2,"freeCashflow":-1955250,"operatingCashflow":-1598000,"totalDebt":63206000,"debtToEquity":40.9,"currentRatio":5.68,"returnOnAssets":-1.1,"returnOnEquity":85.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":9,"targetMeanPrice":22.78,"targetHighPrice":26,"targetLowPrice":18,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.4,"institutionHeldPercent":65.8,"sharesOutstanding":58711584,"floatShares":54409199,"sharesShort":4719963,"shortRatio":3.42,"shortPercentOfFloat":8,"epsTrailing":1.34,"epsForward":1.52,"revenuePerShare":1.93,"bookValue":2.72,"officers":[{"age":52,"name":"Mr. Neil F. McFarlane","title":"President, CEO & Director"},{"age":63,"name":"Dr. Adrian  Quartel FFPM, M.D.","title":"Chief Medical Officer"},{"age":53,"name":"Mr. Justin A. Renz CPA, MBA","title":"CFO & Treasurer"},{"age":null,"name":"Ms. Nichol L. Ochsner","title":"Vice President of Investor Relations & Corporate Communications"},{"age":53,"name":"Mr. Rahsaan W. Thompson J.D.","title":"Chief Legal Officer, Secretary & Compliance Officer"},{"age":null,"name":"Ms. Alison  Peters","title":"Chief People Officer"},{"age":50,"name":"Dr. Christopher M. Lauderback Ph.D.","title":"Senior Vice President of Manufacturing"},{"age":53,"name":"Mr. Joshua M. Schafer M.B.A.","title":"Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.zevra.com","phone":"(888) 958-1253"}}